for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

65.17USD

Change

-0.54(-0.82%)

Volume

2,036,238

Today's Range

64.89

 - 

65.96

52 Week Range

42.49

 - 

68.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
65.71
Open
65.63
Volume
2,036,238
3M AVG Volume
364.85
Today's High
65.96
Today's Low
64.89
52 Week High
68.34
52 Week Low
42.49
Shares Out (MIL)
2,344.19
Market Cap (MIL)
154,880.90
Forward P/E
--
Dividend (Yield %)
2.72

Next Event

Bristol-Myers Squibb Co Investor Day

Latest Developments

More

Bristol-Myers - FDA Accepts For Priority Review Co's Biologics License Application (BLA) For Lymphoma Drug

Biomotiv And Bristol-Myers Squibb Announce The Launch Of Anteros Pharmaceuticals

Bristol-Myers Squibb Withdraws European Application Of Opdivo Plus Yervoy For First-Line Treatment Of Advanced Non-Small Cell Lung Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Contact Info

430 E 29th St Fl 14

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

Charles A. Bancroft

Chief Financial Officer, Executive Vice President - Global Business Operations

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President

Sandra Leung

Executive Vice President, General Counsel

Christopher S. Boerner

Executive Vice President and Chief Commercial Officer

Key Stats

1.88 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

20.8K

2018

22.6K

2019

26.1K

2020(E)

42.1K
EPS (USD)

2017

3.010

2018

3.980

2019

4.690

2020(E)

6.131
Price To Earnings (TTM)
30.08
Price To Sales (TTM)
5.92
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
30.40
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Compugen Announces Phase 1/2 Triple Combination Study To Evaluate Com701 In Combination With Bristol-Myers Squibb's Opdivo (Nivolumab) And Tigit Inhibitor

* COMPUGEN ANNOUNCES PHASE 1/2 TRIPLE COMBINATION STUDY TO EVALUATE COM701 IN COMBINATION WITH BRISTOL-MYERS SQUIBB'S OPDIVO® (NIVOLUMAB) AND TIGIT INHIBITOR

BRIEF-Bristol-Myers - FDA Accepts For Priority Review Co's Biologics License Application (BLA) For Lymphoma Drug

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS FOR PRIORITY REVIEW BRISTOL-MYERS SQUIBB’S BIOLOGICS LICENSE APPLICATION (BLA) FOR LISOCABTAGENE MARALEUCEL (LISO-CEL) FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

Bristol-Myers earnings rise due to Celgene contribution

Bristol-Myers Squibb Co <BMY.N> said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included some revenue from Celgene, which the U.S. drugmaker bought in a $74 billion deal that closed in late November.

Bristol-Myers earnings rise due to Celgene deal

Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included some revenue from Celgene, which the U.S. drugmaker bought in a $74 billion deal that closed in late November.

Bristol-Myers pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe as an initial treatment for advanced lung cancer, after regulators there balked at changes to the design of its clinical trials.

CORRECTED-UPDATE 1-Bristol-Myers Squibb pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe as an initial treatment for advanced lung cancer, after regulators there balked at changes to the design of its clinical trials.

CORRECTED-Bristol-Myers pulls Opdivo+Yervoy lung application in Europe

Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe as an initial treatment for advanced lung cancer, after regulators there balked at changes to the design of its clinical trials.

Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive

Bristol-Myers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of the U.S. biotech company, Bristol's chief medical officer said.

FDA approves first generic of Bristol-Myers, Pfizer's blood thinner Eliquis

The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis.

Bristol-Myers wins $752 million in U.S. patent case against Gilead

Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

Bristol-Myers prevails over Gilead in Yescarta royalty row - Bloomberg Law

Bristol-Myers Squibb Co won a patent infringement trial against Gilead Sciences Inc's unit Kite Pharma over cancer immunotherapy Yescarta, Bloomberg Law reported on Friday.

Bristol-Myers business development head Biondi departs

Bristol-Myers Squibb Co's <BMY.N> head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday.

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial.

UPDATE 1-Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up